Zydus Lifesciences Limited disclosed through a press release dated October 15, 2026, that its proposed joint venture company, Zydus Sunshine Lifesciences (Pvt) Ltd, has signed an agreement with the Board of Investment of Sri Lanka.
The agreement was signed on October 13, 2026, for the establishment of a pharmaceutical manufacturing facility in the BOI zone in Horana, Sri Lanka. The joint venture between Zydus Lifesciences Limited and Sunshine Healthcare (part of Sunshine Holdings PLC) was originally announced on June 26, 2026.
Project Details:
- Phased investment totaling over USD 20 million
- Facility to be developed on a site of nearly four acres
- Commercial operations expected to commence in 2028
- Project timeline and regulatory approvals required for commencement
Manufacturing Focus:
- First phase will manufacture oral solid dosage forms
- Production primarily for the Sri Lankan market
Strategic Rationale:
- Supports Zydus' international presence expansion
- Enhances commitment to expanding access to quality medicines
- Expected to strengthen medicine supply chain resilience in Sri Lanka
- Supports availability of essential medicines in Sri Lanka
The disclosure was submitted to BSE Limited and National Stock Exchange of India Limited as a regulatory requirement. The communication was signed by Dhaval N. Soni, Company Secretary and Compliance Officer of Zydus Lifesciences Limited.